估算肾小球滤过率与肌酐清除率预测唑来膦酸相关急性肾损伤的比较
该研究在英國谢菲尔德教学医院代谢性骨中心回顾性分析了2015年9月至2020年10月接受唑来膦酸治疗的4405例患者(共7660次输注),比较eGFR与CrCl预测输注后14天内急性肾损伤(AKI)的能力。结果显示eGFR预测AKI不劣于CrCl,且按MHRA推荐的CrCl<35 ml/min截断值敏感性差,建议日常实践使用eGFR评估肾功能。
要点
- eGFR预测唑来膦酸后AKI的能力至少与CrCl相当。
- MHRA推荐的CrCl<35 ml/min截断值敏感性差。
- 建议使用eGFR评估肾功能,eGFR<50 ml/min/1.73m2时输注30分钟。
核心结论
- eGFR预测AKI的能力至少与CrCl相当,且允许更多高骨折风险患者接受治疗,推荐使用eGFR评估唑来膦酸治疗前的肾功能。
- 对于eGFR<50 ml/min/1.73m2的患者,建议输注时间延长至30分钟。
研究设计与样本
- 回顾性评估,在英国谢菲尔德教学医院代谢性骨中心进行,纳入2015年9月1日至2020年10月1日所有接受唑来膦酸治疗的患者。
- 共纳入4405例患者,总计7660次输注。
主要发现
- 7660次输注中,969次有输注后14天内肌酐数据,其中45次(4.6%)观察到AKI。
- 1例患者死于肺炎,1例患者需要持续血液透析。
- 24次输注在1年内观察到严重AKI(肌酐升高三倍和/或eGFR<15 ml/min/1.73m2)。
- 若遵循MHRA建议,996次基线CrCl<35 ml/min的输注将不被给予;其中142次有14天内血肌酐随访数据,仅4次(2.8%)发生AKI。
- 逻辑回归显示CrCl和eGFR均是预测14天内AKI的显著因素,但当前推荐的CrCl 35 ml/min截断值敏感性差。
关键数值与推荐
- MHRA 2019年建议:应使用CrCl而非eGFR,且CrCl<35 ml/min时不应治疗。
- AKI定义为输注后14天内观察到急性肾损伤。
- 严重AKI定义为肌酐升高三倍和/或eGFR<15 ml/min/1.73m2。
- 推荐eGFR<50 ml/min/1.73m2时输注时间30分钟。
临床怎么用
- 日常实践中使用eGFR而非CrCl来评估接受唑来膦酸治疗骨质疏松患者的肾功能。
- eGFR<50 ml/min/1.73m2的患者,唑来膦酸输注时间应设为30分钟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Zoledronate could be contributing to the development of acute kidney injury in a small number of patients. Since estimated glomerular function (eGFR) is simpler to obtain and at least as good a predictor as creatinine clearance (CrCl), it should be used in everyday practice. INTRODUCTION: Zoledronate is widely used for the treatment of osteoporosis. A potential side effect is acute kidney injury (AKI). Advice from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in 2019 stated that CrCl and not estimated glomerular filtration rate (eGFR) should be used and that treatment should not be given if CrCl < 35 ml/min. The objective of this study was to compare our current method of assessing renal function (eGFR) with the method proposed by the MHRA (CrCl) for predicting AKI after zoledronate infusions. METHODS: The evaluation was performed at the Metabolic Bone Centre in Sheffield Teaching Hospitals, UK. Data on all the patients who had zoledronate from 1/09/2015 to 1/10/2020 were included. RESULTS: Data on 4405 patients were retrieved (total number of infusions 7660). Creatinine in the 14 days post-infusion was available for a total of 969 infusions and AKI was observed within 14 days following 45 infusions (4.6%). One patient died due to pneumonia. One patient needed continued haemodialysis. Severe AKI (threefold in creatinine and/or eGFR < 15 ml/min/173 m2) was observed within 1 year following 24 infusions. If the MHRA recommendations had been followed, 996 infusions with baseline CrCl < 35 ml/min would not have been given. Of these, follow-up data on serum creatinine within 14 days were available for 142 infusions, showing AKI in only four (2.8%). Logistic regression showed that both CrCl and eGFR were significant factors in predicting AKI within 14 days, but that the current recommended cut-off of CrCl 35 ml/min had poor sensitivity. CONCLUSION: Since eGFR is at least as good a predictor of AKI as CrCl, and permits the treatment of more patients at high fracture risk, we recommend that eGFR is used to determine renal function for zoledronate treatment. We suggest that the infusion is given over 30 min in patients with eGFR < 50 ml/min/1.73 m2.
引用
- Schini M, Peel N, Toronjo-Urquiza L, et al. Evaluation of estimated glomerular function (eGFR) versus creatinine clearance (CrCl) to predict acute kidney injury when using zoledronate for the treatment of osteoporosis. Osteoporos Int. 2021. PMID: 34654939. doi:10.1007/s00198-021-06160-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。